Aptar Pharma to showcase an industry first12 Sep 2018
PureHale is a new portable drug delivery device designed for upper respiratory care.
Aptar Pharma will showcase an industry first with its PureHale device – a new portable drug delivery device designed for upper respiratory care - at CPhI Worldwide this year in Madrid.
In addition to PureHale, Aptar Pharma will also reveal:
“Through a wide range of consulting and services, Aptar Pharma innovates around delivery routes, effective drug delivery, testing and regulatory requirements with partners ranging from small-scale R&D firms to the largest international pharmaceutical companies. We look forward to launching our Support Services initiative at CPhI, and working with our customers to meet their development needs, said Guillaume Brouet, Vice President Analytical, Regulatory and Scientific Affairs at Aptar Pharma.”
Along with showcasing its range of innovative drug delivery devices that address nasal, pulmonary, eye care, injectables and dermal drug delivery routes at Aptar Pharma’s exhibit stand, the company will also be sharing various new solutions in prescription and over-the-counter treatments.
Furthermore, Aptar Pharma executives will be delivering three Pharma Insight Briefings outlining the latest trends, technology and product innovations:
“Debunking the leachable myths of gamma sterilization: A migration study of steam vs gamma”
Julie D. Suman, President of Next Breath, a division of Aptar Pharma, Tuesday 9 October, 11:50-12:20.
Julie Suman will present a migration study commissioned by Aptar Pharma to assess the impact of both steam sterilization and gamma sterilization on leachable profiles.
“Portable care for your respiratory tract: Exploring new technology platforms”
Guenter Nadler, Director Business Development, Aptar Pharma, Tuesday 9 October, 12:30-13:00
Guenter Nadler will discuss new trends in treating upper respiratory tract issues naturally, including new respiratory technology platforms that will meet new market needs.
“Building a connected devices eco-system for digital medicines”
Sai Shankar, Director Business Development, Aptar Pharma Wednesday 10 October, 13:50-14:20.
Sai Shankar will highlight the need for a digital medicine eco-system to ensure connected devices are fully optimised through patient-centric design, secure data collection and management, and cross-platform interoperability.
BIA Separations expands with new upstream processing facility
20 Sep 2018
Provides single source of expertise for scaled production of complex biologics for gene therapy and vaccines.Read more
Sanofi to refocus two global business units
19 Sep 2018
The new Primary Care and China & Emerging Markets global business units are expected to launch at the beginning of 2019.Read more
Experts warn trade and patent changes could increase healthcare cost by $100bn over next 5 years
18 Sep 2018
China is harmonizing to ICH standards at feverish pace and will force poor quality manufacturers out of market.Read more
Recipharm connects to European Hub for serialisation compliance
18 Sep 2018
Connection allows the marketing authorisation holders within the Recipharm Group to continue to supply medicines to patients post the EU FMD implementation date.Read more
Bosch to unveil new laboratory device for continuous manufacturing
18 Sep 2018
The Xelum R&D offers pharmaceutical manufacturers an ideal start to continuous OSD production.Read more
Partnership to deliver integrated, off-the-shelf biosimilar manufacturing solutions
17 Sep 2018
Pall and Aetos to advance the market impact of biosimilars and deliver lower-priced, high-quality options to end users.Read more
Cambrex expands manufacturing footprint with acquisition
16 Sep 2018
Completed acquisition adds formulation development and finished dosage manufacturing capabilities to Cambrex’s existing global API manufacturing network.Read more
NMPA approves fruquintinib capsules for metastatic colorectal cancer
13 Sep 2018
Fruquintinib - innovative medicine that has not previously been launched in China or internationally - provides a new therapeutic approach for metastatic colorectal cancer patients.Read more
Novartis to divest the Sandoz US dermatology business and generic US oral solids portfolio
11 Sep 2018
The Sandoz US portfolios to be sold to Aurobindo include approximately 300 products, as well as additional development projects.Read more
New SGS biopharmaceutical testing capabilities in Illinois
11 Sep 2018
The new services will focus on quality control analysis and stability testing of biopharmaceuticals.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation